Ultragenyx Pharmaceutical Inc. (RARE) and Checkpoint Therapeutics Inc. (NASDAQ:CKPT) Comparing side by side

We are comparing Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Checkpoint Therapeutics Inc. (NASDAQ:CKPT) on their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ultragenyx Pharmaceutical Inc. 51.49M 75.72 197.61M -3.90 0.00
Checkpoint Therapeutics Inc. N/A 137.96 30.67M -1.16 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of Ultragenyx Pharmaceutical Inc. and Checkpoint Therapeutics Inc.

Profitability

Table 2 represents Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Checkpoint Therapeutics Inc. (NASDAQ:CKPT)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ultragenyx Pharmaceutical Inc. -383.78% -29.3% -25.4%
Checkpoint Therapeutics Inc. 0.00% -139% -104.3%

Liquidity

The Current Ratio and a Quick Ratio of Ultragenyx Pharmaceutical Inc. are 7 and 6.9. Competitively, Checkpoint Therapeutics Inc. has 3.5 and 3.5 for Current and Quick Ratio. Ultragenyx Pharmaceutical Inc.’s better ability to pay short and long-term obligations than Checkpoint Therapeutics Inc.

Analyst Recommendations

The Recommendations and Ratings for Ultragenyx Pharmaceutical Inc. and Checkpoint Therapeutics Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ultragenyx Pharmaceutical Inc. 0 3 6 2.67
Checkpoint Therapeutics Inc. 0 0 0 0.00

Ultragenyx Pharmaceutical Inc.’s consensus target price is $70.78, while its potential upside is 3.68%.

Insider and Institutional Ownership

Roughly 0% of Ultragenyx Pharmaceutical Inc. shares are owned by institutional investors while 11.2% of Checkpoint Therapeutics Inc. are owned by institutional investors. Insiders owned roughly 0.4% of Ultragenyx Pharmaceutical Inc.’s shares. On the other hand, insiders owned about 9.4% of Checkpoint Therapeutics Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ultragenyx Pharmaceutical Inc. 4.21% 33.9% 19.9% -21.29% 36.36% 51.89%
Checkpoint Therapeutics Inc. 8.9% -20.1% 36.3% -19.9% -27.32% 68.13%

For the past year Ultragenyx Pharmaceutical Inc.’s stock price has smaller growth than Checkpoint Therapeutics Inc.

Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. Its biologics product candidates also comprise recombinant human beta -glucuronidase (rhGUS), an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis. The company is also developing range of small-molecule product candidates, such as UX007, a substrate replacement therapy that is in Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and aceneuramic acid extended-release (Ace-ER), an oral formulation of sialic acid, which is in Phase III extension study to treat GNE myopathy. It has collaboration and license agreements with Arcturus Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Kyowa Hakko Kirin Co. Ltd.; Saint Louis University; Baylor Research Institute; Nobelpharma Co., Ltd.; Alcami Corporation; HIBM Research Group; and St. Jude ChildrenÂ’s Research Hospital. The company was founded in 2010 and is headquartered in Novato, California.

Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. Its pipeline consists of human, immuno-oncology, and checkpoint inhibitor antibodies that target programmed death-ligand 1; glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX. The company is also developing three oral, small-molecule, targeted anti-cancer agents that inhibit epidermal growth-factor receptor mutations, the bromodomain and extra-terminal protein BRD4, and poly polymerase. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.